Back to search

France· FR:67183313

REZZAYO 200 mg, poudre pour solution à diluer pour perfusion

A rezafungin acetate product containing acétate de rézafungine, registered in France by MUNDIPHARMA (ALLEMAGNE). The same ATC class is registered in 10 of our 19 countries.

ATC J02AX08

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedREZZAYO 200 mg, poudre pour solution …ATCJ02AX08REGISTER NO.FR:67183313PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Rezafungin acetate is registered in 10 of 19 countries.

Countries holding a registration under ATC J02AX08 (rezafungin acetate), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 7 of them publish a price we can compare per daily dose

Rezafungin acetate · ATC J02AX08

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ACÉTATE DE RÉZAFUNGINE
Manufacturer
MUNDIPHARMA (ALLEMAGNE)
Country
France (FR)
ATC code
J02AX08
ATC class
Rezafungin acetate
Defined daily dose
28.6 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955098843
    1 flacon(s) en verre

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7da1f34c-046e-49da-8385-58176352c635
GET /v1/drugs/7da1f34c-046e-49da-8385-58176352c635?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "67183313",
  "date_amm": "2023-12-22",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/23/1775",
  "substance": "ACÉTATE DE RÉZAFUNGINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about rezafungin acetate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.